New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2012
07:18 EDTCRISCuris announces U.S. patent issuance covering HSP90 inhibitor Debio 0932
Curis announced that the U.S. Patent and Trademark Office has issued a patent covering a genus of compounds that includes Debio 0932, an orally-administered Heat Shock Protein 90, or HSP90, inhibitor, which is being developed by Curis' licensee Debiopharm. The newly issued patent, U.S. Patent Number 8,324,240, is entitled "Fused Amino Pyridine as HSP90 Inhibitors."
News For CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
07:21 EDTCRISCuris announces allowance of U.S. patent
Curis announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials. This patent, along with prior patents issued to Curis, further strengthens the Company's intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a single small molecule for the treatment of certain human diseases. Collectively, these patents generically cover composition-of-matter and methods of use of CUDC-907 as well as a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin, within a single molecule for the treatment of certain human diseases.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use